PLATELET DRUGS AND DISORDERS

Diagnosis and Management of Immune Thrombocytopenia in the Era of Thrombopoietin Mimetics

Howard A. Liebman1 and Vinod Pullarkat1
1Keck

School of Medicine, University of Southern California, Los Angeles, CA

The recognition of that patients with Immune Thrombocytopenia (ITP) have functional thrombopoietin deciency and decreased platelet production due to immune-mediated megakaryocytic injury has challenged the traditional view of this disease as predominantly a disorder of antibody-mediated platelet destruction. The therapy of chronic refractory ITP has been transformed by the approval of the thrombopoietin minetics, romiplostim and eltrombopag, which have shown remarkable efcacy in randomized trials. The use of these agents earlier in the disease course after failure of corticosteroid therapy remains controversial. In this article, we review the current data on the efcacy and safety of thrombopoietin receptor agonists and discuss other therapies as well as diagnostic work up of ITP.

Introduction
Immune thrombocytopenia (ITP) is a heterogeneous autoimmune disorder characterized by thrombocytopenia with or without mucocutaneous bleeding manifestations. Because of its complex pathophysiology and its association with a variety of other disorders, ITP is best characterized as a syndrome sharing the common clinical phenotype of immune-mediated thrombocytopenia.1

ITP and to provide additional information to assist with patient management. A complete blood count should reveal isolated thrombocytopenia with normal white and red blood cell numbers. Anemia may exist if there has been signicant acute or chronic blood loss or concomitant immune hemolytic anemia (Evan syndrome). A careful review of the peripheral blood smear is mandatory to exclude other causes of thrombocytopenia. Abnormalities in erythrocyte or leukocyte morphology may suggest an underlying BM disorder such as myelodysplastic syndrome or a congenital cause of thrombocytopenia. The presence of a MYH9-related disorder may be suggested by leukocyte inclusion bodies. Many congenital thrombocytopenic disorders are associated with very large platelets (macrothrombocytopenia), which may also be reected in an abnormally high mean platelet volume. Increased numbers of small lymphocytes or lymphocytes with granular inclusions may suggest a diagnosis of chronic lymphocytic leukemia or large granular lymphocytic leukemia with secondary ITP. Pseudo-thrombocytopenia due to platelet clumping should be excluded, and if platelet clumping is seen on the blood smear, a repeat platelet count using a blood sample collected in citrate or heparin rather than EDTA should be performed. Thrombocytopenia resulting from thrombotic thrombocytopenic purpura or hemolytic uremic syndrome must be considered if the blood smear shows signicant numbers of schistocytes. The international working group on ITP recommended several additional laboratory tests to further assist in the diagnosis and management of patients with primary ITP5 (Table 1). BM examination has been recommended in patients refractory to ITP therapy or in those who relapse after an initial remission, patients with systemic symptoms or atypical physical ndings, and patients before splenectomy.5 A BM aspirate and biopsy should be performed in patients older than 60 years and should include cytogenetic studies and ow cytometry.5

Denition and epidemiology

ITP is an acquired disorder characterized by isolated thrombocytopenia with a peripheral blood platelet count 100 109/L in the absence of any obvious initiating or underlying cause.2 Therefore, the diagnosis of ITP is one of exclusion and is based principally on patient history, physical examination, complete blood count, and review of the peripheral blood smear.3 The recent ITP international working group consensus report has divided the disorder into three phases: newly diagnosed ITP ( 3 months), persistent ITP (3 months-1 year), and chronic ITP ( 1 year).2 ITP can be further characterized as being either primary (idiopathic) or secondary to several associated disorders such as immunodeciency diseases, autoimmune-rheumatologic disorders, lymphoproliferative diseases, and certain chronic infections.2 It is estimated that 20% of ITP cases in the United States are secondary to other disorders.1 However, the incidence of secondary ITP worldwide may vary greatly, particularly in populations with a high incidence of HIV, hepatitis C, or Helicobacter pylori infection. The incidence of newly diagnosed ITP in adults ranges from 1.6-3.9 per 100 000 persons per year.4 Recent studies have found an increased incidence and prevalence with advancing age.4 The female-to-male ratio ranges from 1.2-1.9, with the female predominance more evident among young to middle-age adults.4

Diagnostic approach to patients with suspected ITP

A presumptive diagnosis of ITP is made by a careful history, physical examination, complete blood count, and review of the blood smear.3,5 Response to initial treatment with corticosteroids, intravenous immunoglobulin (IVIg), or anti-RhD supports the diagnosis and conrms the immune nature of the thrombocytopenia. However, additional investigation is necessary to exclude secondary

Clinical presentation and natural history of ITP in adults

Adult patients with ITP are more likely to manifest disease with a chronic course. Overall, 15% of patients remit within 1 year after disease onset, but rare late remissions occur, even among patients who have failed splenectomy.6,7 Bleeding manifestations are the

384

American Society of Hematology

Table 1. International ITP Working Group consensus recommendations for the diagnosis of ITP in children and adults Basic initial evaluation Patient history Family history Medication history Physical examination Complete blood count Quantitative immunoglobulins Blood group (Rh) Direct antiglobulin test H pylori HIV HCV BM (in selected patients) Additional studies of potential value Antiphospholipid antibodies (patients with history of thrombosis or fetal loss) TSH or antithyroid antibodies ANA in children Pregnancy test in women of childbearing years Viral PCR for parvovirus and CMV (selected refractory, febrile, or leukopenic patients) Platelet glycoprotein-specic antibodies Studies of unproven benet Thrombopoietin assay Reticulated platelets Platelet-associated immunoglobulins Serum complement Bleeding time Platelet survival studies

(Adapted with permission from Provan et al.5) HCV indicates hepatitis C virus; TSH, thyroid-stimulating hormone; and ANA, antinuclear antibody.

most common presenting symptoms in patients with ITP, but the increased use of automated blood counts results in the frequent identication of asymptomatic patients or patients with minimal bleeding. Therefore, it is uncertain whether there is a period of mild to moderate thrombocytopenia in adults before the development of severe thrombocytopenia with bleeding. In a study of 217 healthy subjects with incidentally discovered thrombocytopenia and platelet counts between 100 109/L and 150 109/L, the 10-year probability of developing ITP as dened by platelet counts 100 109/L was 6.9% (95% condence interval: 4.0%-12.0%). The 10-year probability of developing autoimmune disorders other than ITP was 12% (95% condence interval: 6.9%-20.8%).8 Mucocutaneous bleeding, including petechiae, purpura, epistaxis, and gum bleeding, is the most common initial manifestation of ITP. Complications of internal bleeding or fatal intracranial hemorrhage are rare and more often occur in older individuals with additional comorbidities.6,7 Symptomatic bleeding is to a degree related to the platelet count, with nearly all major bleeding occurring with platelet counts 30 109/L. Only in patients with hepatitis Crelated thrombocytopenia does major bleeding appear to occur with some frequency at higher platelet counts.9 The risk of bleeding and fatal hemorrhage in adults with severe chronic ITP, dened as a platelet count of 30 109/L at least 1 year after diagnosis, was analyzed in a pooled analysis of published clinical series comprising 1800 patients.10 The annual incidence of fatal hemorrhage was 1.6-3.9 cases per 100 patient years, with a lower risk in patients 40 years of age (0.4% per year) compared with patients 60 years of age (13% per year).10 The risk of nonfatal hemorrhage was estimated to be 3% per year in patients 40 years of age and 71% per year for patients 60 years of age. However, it should be noted that this case series dated from 1954 to 1991 and therefore did not include patients treated with newer agents (eg, rituximab and thrombopoietin [TPO] receptor agonists) or managed with laparoscopic splenectomy.

cine, have been associated with the subsequent development of ITP in children.1,11,12 Signs of mucocutaneous bleeding most often occur without other systemic symptoms, and the child frequently does not appear ill.12 Bleeding manifestations vary from little or none to the typical ndings of purpura, petechiae, epistaxis, and menorrhagia in older females.12 Most children present with platelet counts 20 109/ L.13 In a study of 863 children with newly diagnosed ITP, none or mild bleeding manifestations were reported in 77% of patients, moderate bleeding occurred in 20%, and severe bleeding in 3%.13 Life-threatening bleeding is rare and the estimated risk of intracranial hemorrhage is between 0.1% and 0.5% in newly diagnosed cases.11-13 Approximately 65%-70% of children remit by 6 months and another 15%-20% by 12 months.11,12 The 5%-10% of children who develop chronic ITP tend to be older, are more often female, and usually present with a higher platelet count.12

Pathophysiology of ITP
Assays specic for auto-antibodies directed against specic plateletspecic glycoproteins can detect antibodies in 40%-80% of patients with clinical ITP.14 However, the absence of detectable antibodies does not rule out a diagnosis of ITP, because many patients without detectable antibodies respond to traditional ITP therapies, and antibodies may occur in patients with liver disease and other conditions without clinical ITP. The antigenic target for these antiplatelet auto-antibodies are the ubiquitous platelet glycoproteins such as platelet GPIIb/IIIa in nearly 2/3 of patients, platelet GPIb/IX in approximately 1/5 of patients, and in the remaining patients, antibodies are directed against both of these platelet glycoprotein complexes or other platelet antigens. Dendritic cells from patients with ITP have up-regulated costimulatory molecules enhancing auto-reactive T- and B-cell responses against platelets.15 The ongoing process of macrophage-mediated platelet destruction and further presentation of new platelet proteins to T and B lymphocytes contributes to the epitope spreading observed over time in patients with ITP, and may contribute to a more refractory disease in patients with ITP of longer duration.1 ITP patients may have signicant defects in immune selftolerance.1,15 Autoreactive cytotoxic CD8-expressing T-lymphocyte clones capable of directly damaging platelets and possibly megakaryocytes have also been demonstrated16 and are likely to proliferate under the inuence of similar Th lymphocytes. Quantitative and

Clinical presentation and natural history of ITP in children

The peak age of presentation of ITP in children is between 5 and 6 years, with 70% of cases presenting between ages of 1 and 10 years.11 Approximately 50%-60% of children will have a febrile illness that preceded the discovery of thrombocytopenia. Numerous viral infections, including rubella, varicella, mumps, rubeola, and EBV, as well as immunizations with measles-mumps-rubella vac-

Hematology 2011

385

qualitative defects in the regulatory T-cell population appear to be correlated with persistence of chronic ITP. An association between an improvement in the peripheral blood regulatory T-cell number and function and remission induction with ITP treatment has also been reported.15

When used alone, 65%-70% of patients respond.5,24,25 Responses in adults are rarely durable, with only 13%-17% of patients having an unmaintained normal platelet count at 1 year after treatment with prednisone alone.5,24,25 Early studies on the use of high-dose dexamethasone for the treatment of refractory ITP were abandoned due to signicant toxicity and marginal efcacy.26 More recently, a study of a single course of high-dose dexamethasone (40 mg/d 4 days) in newly diagnosed patients reported a high initial response (85%), with half of the responding patients maintaining their response at 6 months.27 A multicenter trial of dexamethasone (40 mg/d 4 days) repeated every 14 days for 4 courses produced an 86% response rate (platelet count, 50 109/L) and a 65% complete response rate (platelet count 100 109/L).28 At a 15-month median follow-up, 60% of responding adults had not relapsed, and for both adults and children who obtained a complete response, 87% remained in remission.28 However, a recently reported randomized trial comparing 1 or 2 cycles of the high-dose dexamethasone to 1 mg/kg prednisolone failed to demonstrate superiority of the dexamethasone regimen.29 Additional studies will be needed to prove that this approach provides superior long-term benet.

Suppression of platelet production

Using indium-111labeled autologous platelets, investigators have found evidence not only of increased platelet clearance, but also of impaired platelet production.17,18 Recent studies have demonstrated inhibition of in vitro megakaryocyte growth and maturation by antibodies from some ITP patients.19 Evidence that patients with ITP have autoreactive cytotoxic thymic (T) lymphocytes capable of directly lysing platelets suggests that these lymphocytes may also induce megakaryocyte injury and contribute to defective platelet production.16 Whereas megakaryocyte numbers and appearance in BM specimens appear normal in most patients with ITP when viewed under light microscopy, electron microscopic studies of BM from ITP patients show extensive damage in the majority of megakaryocytes.20 TPO is the major physiologic regulator of megakaryocyte growth and differentiation.21,22 It is synthesized and secreted by the liver, and its production is constant, with no translational or posttranslational regulation.21 When TPO is released into the circulation, most of the protein binds to TPO receptors on platelets and is cleared, with the platelets with the remaining TPO binding to receptors on BM precursors.21 TPO levels are inappropriately low for the degree of thrombocytopenia in the majority of patients with ITP, and this observation provided the theoretical basis for treatment with TPO-receptor agonists.21,23

IVIg and IV anti-RhD

Several treatment trials have clearly demonstrated that in 65%-80% of patients treated with IVIg, the platelet counts increase within 24-48 hours.3,5,30 Duration of response is rarely greater than 10-14 days. Initial treatment regimens, in which 0.4 g/kg was infused daily for 5 days, have been supplanted by a higher-dose regimen of 1 g/kg daily for 1 or 2 days. This latter regimen is associated with longer daily infusion time and greater toxicity, including infusion reactions, headaches, occasional aseptic meningitis, hemolytic anemia due to alloantibodies, acute renal failure, and rare thrombotic events, primarily in the elderly. The concomitant use of corticosteroids may enhance the platelet response, reduce infusion reactions, and result in fewer headaches. Patients who are Rh positive, not signicantly anemic, and still have their spleens are candidates for treatment with anti-RhD. Before initiating treatment with anti-RhD, patients should be Rh typed and have a direct antiglobulin test performed. Treatment with the US Food and Drug Administration (FDA)approved dose of 50 g/kg can result in an increase in the platelet count to 50 109/L in nearly 80% of patients, but requires 48-72 hours for a clinically signicant response.3,5,31 Infusions of 75 g/kg have been associated with a more rapid increase in the platelet count equivalent to that reported with IVIg treatment.32 The duration of response to anti-RhD therapy is usually longer than that observed with IVIg treatment, averaging 21 days.33 Treatment with anti-Rh immunoglobulin typically results in a mild hemolytic anemia with an average decrease in hemoglobin of 1-1.5 g. Occasional episodes of intravascular hemolysis resulting in renal failure and rare cases of disseminated intravascular coagulation and death have also been reported.5

Management of primary ITP in adults

Several factors, including bleeding risk, toxicities of specic therapies, patient age and comorbidities, and patient preference and lifestyle, must be considered before treatment is initiated in adults with primary ITP.5 For children with ITP, when treatment is given, it is initially aimed at rapidly increasing the platelet count to a safe level, then maintaining an adequate and safe count while awaiting a spontaneous remission. For adults, most of whom will have chronic ITP, therapies are used to increase the platelet count to a safe level and/or to prevent further bleeding with minimal toxicities. Maintenance of a platelet count 30 109/L is an appropriate goal. Treatment should be considered when the platelet count is 2030 109/L, but occasionally it is appropriate to select a higher target count.5 For secondary ITP, treating the underlying disease is usually the preferred approach.

Corticosteroid therapy
Corticosteroids are the standard initial therapeutic agents5 and those used most frequently include prednisone, parenteral methylprednisolone, and dexamethasone. These are frequently used in combination with IVIg and IV anti-RhD to rapidly increase platelet counts in patients with signicant thrombocytopenia ( 5 109/L) and extensive bleeding manifestations.5 Prednisone is the steroid most frequently used in the treatment of ITP, and is given orally at a dose of 0.5-2 mg/kg daily. In responders, the platelet count will increase to 50 109/L in a few days to several weeks, depending upon the baseline platelet count and whether IVIg or anti-RhD is used in conjunction with the drug. Bleeding may cease before an increase in the platelet count is seen.

Splenectomy
Splenectomy is the historical gold standard for the treatment of chronic ITP. A systematic review of the medical literature has shown that 65% of patients will have unmaintained remissions lasting 10 years or longer. In the majority of these patients, the procedure appears to be curative.34 The response rate in the rst week is nearly 85%, with 20% of patients relapsing within weeks to years.34 However, even after relapse, patients appear to be less

386

American Society of Hematology

refractory to medical treatment.34 Patients older than 45 years appear to have a lower response to splenectomy.34 At present, there are no readily available clinical or laboratory markers that are predictive of response to splenectomy, although there it has been suggested that hepatic sequestration of autologous indium-111 labeled platelets may be predictive of a poor response.35 Laparoscopic splenectomy is associated with lower complication rates and faster recovery, no greater need for accessory splenectomy, and no loss in efcacy.36 Splenectomized patients should have yearly inuenza vaccinations and, if a fever occurs, the patient should immediately receive parenteral broad-spectrum antibiotics that are effective against pneumococcus. This is true no matter how many years have elapsed since the splenectomy and despite immunization. Other long-term outcomes after splenectomy are unknown, particularly in regard to uncommon events such as pulmonary hypertension or vascular dementia.37,38

no rescue therapy) was seen in 38% of splenectomized patients and in 61% of nonsplenectomized patients. The overall response rate (platelet count, 50 109/L on 4 of 24 weeks) was 79% in splenectomized patients and 88% in nonsplenectomized patients.45 There were no responses in the splenectomized patients and only a 14% response rate in nonsplenectomized patients taking placebo. There were signicant reductions in the use of concomitant medications such as prednisone and reduced use of rescue medications (eg, IVIg, anti-RhD, or prednisone).45 No tachyphylaxis was seen over the 6 months of study, nor did any important toxicities emerge, such as an increased incidence of thromboembolic events or myeloid malignancies. Due to rare instances of increased BM reticulin that were observed in patients at higher doses, the highest recommended dose for treatment is now 10 g/kg. Rebound thrombocytopenia with platelet counts decreasing to less than pretreatment baseline levels occurred in up to 5%-10% of patients who stopped treatment abruptly. Romiplostim was licensed in August 2008 based on these 2 studies. Patients who entered 1 of the 2 previous studies were eligible to enter a long-term maintenance study validating the efcacy and safety of romiplostim use for up to 3 years of follow-up.46 Overall, this study showed that the long-term use of romiplostim as a maintenance therapy was feasible. Platelet counts could be maintained for years without the need to signicantly increase the dose. Many patients learned to give weekly injections at home. No important new toxicities were identied with extended use. Nine cases of BM reticulin brosis were identied, but no cases of myelobrosis/myeloid metaplasia. Whether this incidence is signicantly higher than that which occurs in patients with ITP successfully treated with other agents requires additional study. An open-label, 52-week randomized trial of romiplostim versus standard of care reported a higher rate of platelet response (platelet count, 50 109/L at any scheduled visit), lower incidence of treatment failure and splenectomy, and less bleeding in the romiplostim-treated patients The starting romiplostim dose in this study was 3 g/kg and the rate of platelet response was 2.3 times that observed in the standard-of-care group.47 However, utility beyond 52 weeks compared with patients who were treated with splenectomy is unknown. Another study has reported safety and efcacy of romiplostim in 22 children.48 In this small, 12-week randomized trial of patients 12 months to 18 years of age, platelet counts of 50 109/L for 2 consecutive weeks was achieved in 88% of patients in the romiplostim group compared with none in the placebo group. Romiplostim treatment was well tolerated, with no serious adverse events.48 Eltrombopag is the rst oral TPO receptor agonist to complete clinical trials and to be licensed for use in the United States. In the initial published study, eltrombopag was given for 6 weeks in daily doses of 30 mg, 50 mg, and 75 mg, and results were compared with patients given placebo.49 Responses were seen in 70%-80% of patients at the 2 highest eltrombopag doses compared with 11% in those receiving placebo.48 No important toxicity was seen and bleeding decreased as the platelet counts increased. A second study reported similar results for thrombocytopenic patients with hepatitis C infection, allowing continued antiviral chemotherapy without dose reduction or interruption.50 A third conrmatory study was a 6-week randomized, placebocontrolled trial that compared 50 mg of eltrombopag against placebo.51 That study demonstrated a 59% response rate in the

Anti-CD20 therapy (rituximab)

B-lymphocyte depletion using rituximab, a humanized anti-CD20 mAb, has shown limited but reproducible efcacy in patients with chronic ITP.39,40 Up to 60% of patients will have an initial increase in their platelet count, with an estimated 1/3 of patients obtaining an initial (1-year) unmaintained complete response (platelet count, 100 109/L) with the use of the standard lymphoma regimen of 375 mg/m2 rituximab weekly for 4 weeks.39,40 Nearly all partial responders will relapse within 1 year, whereas nearly all complete responders will maintain their response for at least 1 year. Approximately one-half of complete responders will relapse within 4 more years. Although repeat treatment of the relapsed complete responder can result in a high rate of response,41 the safety of this approach has not been fully evaluated. Concerns about the use of anti-CD20 therapy include the development of progressive multifocal leukoencephalopathy and reactivation of hepatitis B. These risks may be lower in ITP patients than in patients with lymphoma and other systemic autoimmune disorders, because patients with ITP are generally not intrinsically immunosuppressed by their disease or receiving additional immunosuppressive therapies. Common, but less serious, toxicities include rst-infusion reactions such as fever and chills and serum sickness, the latter being especially common in children.42 Although total Ig levels rarely decrease, patients cannot mount a normal humoral antibody responses to some vaccines for months after treatment. Therefore, it may be preferable to immunize patients before the initiation of rituximab therapy because splenectomy may need to be performed within the 6- to 9-month period after rituximab therapy. The optimal dose and frequency of rituximab administration for the treatment of ITP remains unknown.43

TPO receptor agonists: romiplostim and eltrombopag

Romiplostim was the rst TPO receptor agonist to enter clinical trials.44 Subsequently, 2 randomized, placebo-controlled studies were published, one in splenectomized patients and the other in nonsplenectomized patients.45 In both studies, the same dosing regimen was used with progressive weekly increases in dose depending on the platelet count, beginning at 1 g/kg and increasing to 15 g/kg. Rescue medications were allowed for overt bleeding or very low counts associated with a high risk of bleeding. Concomitant medications such as prednisone could be decreased or stopped as the platelet count increased. In both trials, unequivocal efcacy was demonstrated. Durable response (platelet count, 50 109/L for 6 of the last 8 weeks and

Hematology 2011

387

eltrombopag arm, based on an increase in platelet count to 50 109/L compared with a 16% increase in platelet count in those taking placebo. Bleeding manifestations were decreased in responders, but returned to baseline levels after the medication was discontinued and platelet counts declined. In that study, rebound thrombocytopenia upon drug withdrawal was rare and no statistically signicant organ toxicity was seen. However, some patients developed signicant liver enzyme increases requiring cessation of medication. Accordingly, the FDA has required a black box warning concerning the need to monitor liver function in patients taking eltrombopag.51 A 6-month randomized study trial comparing eltrombopag with placebo showed results comparable to the 6-month pivotal trial of romiplostim.52 A long-term extension study reported in abstract form has conrmed the durability of platelet responses.53 In addition, long-term follow-up of all patients enrolled in eltrombopag trials found a lower frequency of thromboembolic events than was reported in earlier studies.54

sial. Options include: (1) laparoscopic splenectomy, with its low morbidity and the highest documented rate of durable remission; (2) rituximab treatment before splenectomy, with 1 of 5 patients in unmaintained remission at 5 years; or (3) chronic and potentially indenite therapy with a TPO receptor agonist to maintain a safe platelet count without the use of additional immunosuppression or splenectomy. A long-term randomized trial of sequenced postcorticosteroid therapy could provide clinical data for a more logical treatment algorithm.

Disclosures
Conict-of-interest disclosure: H.A.L. has received research funding from Shionogi and Amgen, has consulted for GSK and Amgen, and has been afliated with the speakers bureau for GSK. V.P. has been afliated with the speakers bureau for and received honoraria from Amgen and GlaxoSmithKline. Off-label drug use: This manuscript discusses the use of eltrombopag and romiplostim in liver disease and ritmiximab in ITP.

Correspondence

Monitoring and management of side effects of TPO mimetics

Given the mechanism of action of TPO mimetics, the side effects of concern are the development of BM brosis, venous thromboembolism, myeloid malignancies, and rebound thrombocytopenia. Reticulin brosis (grade 2 or above) is rare with the use of TPO mimetics and can be monitored by paying close attention to blood counts and morphologic abnormalities on peripheral blood smear. The exact incidence of this complication is unclear, but reticulin brosis appears to be a rare, dose-dependent phenomenon that resolves after cessation of the TPO mimetic.55 No signicant increase in incidence of venous thromboembolism has been reported in patients who received romiplostim or eltrombopag compared with the incidence in ITP patients, and thromboembolic events have not been shown to be correlated with platelet counts.54 However, these agents should be used with caution in patients with known predispositions to arterial or venous thrombosis. No increase in myeloid malignancies has been reported so far in patients treated with either agent. The incidence of rebound thrombocytopenia is 10% with either agent and can be managed by close monitoring of platelets count in the 4 weeks after discontinuation of treatment. Patients who develop hepatotoxicity with eltrombopag should not be rechallenged with the drug except under exceptional circumstances. Hepatotoxicity has not been observed with romiplostim.

Howard A. Liebman, Professor of Pathology and Medicine, Division of Hematology, Keck School of Medicine, 1441 Eastlake Ave, NOR 3466, 9172, Los Angeles, CA 90033; Phone: (323) 865-3950; Fax: (323) 865-0060; e-mail: liebman@hsc.usc.edu.

References
1. Cines DB, Bussel JB, Liebman HA, Luning Prak ET. The ITP Syndrome:A diverse set of disorders with different immune mechanisms. Blood. 2009;113:6511-6521. 2. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, denitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113:2386-2393. 3. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura:a practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996;88:3-40. 4. Fogarty PF. Chronic Immune Thrombocytopenia in adults: epidemiology and clinical presentation. Hematol Oncol Clin North Am. 2009;23:1213-1221. 5. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115:168-186. 6. Neylon AJ, Saunders PW, Howard MR, Proctor SJ, Taylor PR. Clinically signicant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a populationbased cohort of 245 patients. Br J Haematol. 2003;122:966974. 7. McMillan R, Durette C. Long-term outcomes in adults with chronic ITP after splenectomy failure. Blood. 2004;104:956960. 8. Stasi R, Amadori S, Osborn J, Newland AC, Provan D. Long-term outcome of otherwise healthy individuals with incidentally discovered borderline thrombocytopenia. PLoS Med. 2006;3:e24. 9. Rajan S, Espina B, Liebman HA. Hepatitis C virus-related thrombocytopenia: clinical and laboratory characteristics compared to chronic immune thrombocytopenic purpura. Br J Haematol. 2005;129:818-824. 10. Cohen YC, Djulbegovic B, Shamai-Lubovitz O, Mozes B. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med. 2000;160:1630-1638.

Single-agent treatment of refractory ITP

Azathioprine, danazol, cyclophosphamide, cyclosporine A, and mycophenolate mofetil have shown limited efcacy in the treatment of ITP. No single agent induces unmaintained remission in 30% of refractory cases, and this is particularly true in patients refractory to splenectomy.56 In one report, pulse cyclophosphamide induced a complete response in 13 of 20 patients, 8 of whom remained in remission with a median follow-up of 2.5 years.57 Even autologous stem cell transplantations have only been found to have a 25%-33% response rate and are without multi-year follow-up data.58

Controversies in ITP therapy

The high response rates reported in randomized trials of refractory postsplenectomy patients treated with TPO receptor agonists have established these agents as the drugs of choice for this group of patients. However, the choice of second-line therapy in newly diagnosed patients who fail corticosteroids is much more controver-

388

American Society of Hematology

11. Ku hne T, Buchanan GR, Zimmerman S, et al. A prospective comparative study of 2540 infants and children with newly diagnosed idiopathic thrombocytopenic purpura (ITP) from the Intercontinental Childhood ITP Study Group. J Pediatr. 2003; 143:605-608. 12. Bennett CM, Tarantino M. Chronic thrombocytopenia in children: epidemiology and clinical presentation. Hematol Oncol Clin North Am. 2009;23(6):1223-1238. 13. Neunert CE, Buchanan GR, Imbach P, et al. Severe hemorrhage in children with newly diagnosed immune thrombocytopenic purpura. Blood. 2008;112:4003-4008. 14. McMillan R. Antiplatelet antibodies in chronic immune thrombocytopenia and their role in platelet destruction and defective production. Hematol Oncol Clin North Am. 2009;23(6):11631175. 15. Semple JW. Infections, antigen-presenting cells, T cells, and immune tolerance: their role in the pathogenesis of immune thrombocytopenia. Hematol Oncol Clin North Am. 2009;23(6): 1177-1192. 16. Olsson B, Andersson P, Jernas M, et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med. 2003;9:1123-1124. 17. Stoll D, Cines DB, Aster RH, et al. Platelet kinetics with idiopathic thrombocytopenic purpura and moderate thrombocytopenia. Blood. 1985;65:584-588. 18. Ballem PJ. Segal GM. Stratton JR, et al. Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance. J Clin Invest. 1987;80:33-40. 19. McMillan R. Wang L. Tomer A. Nichol J. Pistillo J. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood. 2004;103:1364-1369. 20. Houwerzijl EJ, Blom NR, van der Want JJL, et al. Ultrastructural study shows morphological features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura. Blood. 2004;103:500-506. 21. Kuter DJ, Gernsheimer TB. Thrombopoietin and platelet production in chronic immune thrombocytopenia. Hematol Oncol Clin North Am. 2009;23:1193-1211. 22. Kaushansky K. Thrombopoietin. N Engl J Med. 1998;339:74654. 23. Nichol JL. Thrombopoietin levels after chemotherapy and in naturally occurring human diseases. Curr Opin Hematol. 1998;5:203-208. 24. Schiavotto C, Rodeghiero F. Twenty years experience with treatment of idiopathic thrombocytopenic purpura in a single department: results in 490 cases. Haematologica. 1993;78: (suppl 2):22-28. 25. Ben-Yehuda D, Gillis S, Eldor A, Israeli ITP Study Group. Clinical and therapeutic experience in712 Israeli patients with idiopathic thrombocytopenic purpura. Acta Haematol. 1994;91: 1-6. 26. Stasi R, Brunitti M, Pagano A, et al. Pulsed high-dose dexamethasone in adults with chronic thrombocytopenic purpura. Blood Cells Mol Dis. 2000;26:582-586. 27. Cheng Y, Wong RS, Soo YO, et al. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med. 2003;349:831-836. 28. Mazzucconi MG, Fazi P, Bernasconi S, et al. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood. 2007;109:1401-1407.

29. Bae SH, Ryoo H-M, Lee WS, et al. High dose dexamethasone vs. conventional dose prednisolone for adults with immune thrombocytopenia: a prospective multicenter phase III trial [Abstract]. Blood. 2010;116:3687. 30. Newland AC, Treleaven JG, Minchinton RM, Waters AH. High-dose intravenous IgG in adults with autoimmune thrombocytopenia. Lancet. 1983;1:84-87. 31. Bussel JB, Graziano JN, Kimberly RP, Pahwa S, Aledort LM. Intravenous anti-D treatment of immune thrombocytopenic purpura: analysis of efcacy, toxicity, and mechanism of effect. Blood. 1991;77:1884-1893. 32. Newman GC, Novoa MV, Fodero EM, et al.B. A dose of 75 microg/kg/d of i.v. anti-D increases the platelet count more rapidly and for a longer period of time than 50 microg/kg/d in adults with immune thrombocytopenic purpura. Br J Haematol. 2001;112:1076-1078. 33. Scaradavou A, Woo B, Woloski BM, et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients. Blood. 1997;89:2689-2700. 34. Kojouri K, Vesely SK, Terrell DR, George JN. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response and surgical complications. Blood. 2004;104:2623-2634. 35. Sarpatwari A, Provan D, Sobnack R, et al. Autologous 111Inlabeled platelet sequestration studies in patients with primary immune thrombocytopenia (ITP):A report from the United Kingdom registry [Abstract]. Blood. 2009;114:2406. 36. Katkhouda N, Mavor E. Laparoscopic splenectomy. Surg Clin N Am. 2000;80:1285-97. 37. Jas, Loos V, Jardim C, et al. Splenectomy and chronic thromboembolic pulmonary hypertension. Thorax. 2005;60: 1031-1034. 38. Ahn YS, Horstman LL, Jy W, Jimenez JJ, Bowen B. Vascular dementia in patients with immune thrombocytopenic purpura. Thromb Res. 2002;107:337-344. 39. Cooper N, Stasi R, Cunningham-Rundles S, et al. The efcacy and safety of B cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol. 2004;125:232-239. 40. Arnold DM, Dentali F, Crowther MA, et al. Systematic review: efcacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med. 2007;146:25-33. 41. Hasan A, Michel M, Patel V, et al. Repeated courses of rituximab in chronic ITP: three different regimens. Am J Hematol. 2009;84(10):661 665. 42. Wang J, Wiley J, Luddy R, Feuerstein M, Bussel JB. Chronic immune thrombocytopenia purpura (ITP) in children: assessment of rituximab treatment. J Pediatr. 2005;146:217-221. 43. Zaja F. Vianelli N. Volpetti S, et al. Low dose rituximab in adult patients with primary immune thrombocytopenia. Eur J Haematol. 2010;85:329-34. 44. Bussel JB, Kuter DJ, George JN, et al. Effect of a novel thrombopoiesis-stimulating protein (AMG 531) in chronic immune thrombocytopenic purpura. N Engl J Med. 2006;355: 1672-1681. 45. Kuter DJ, Bussel JB, Lyons RM, et al. Efcacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomized controlled trial. Lancet. 2008;371:395403. 46. Bussel JB, Kuter D, Pullarkat VA, Lyons R, Guo M, Nichol J. Safety and efcacy of long-term treatment with romiplostim in

Hematology 2011

389

47.

48.

49.

50.

51.

52.

thrombocytopenic patients with chronic ITP. Blood. 2009;113: 2161-2171. Kuter DJ, Rummel M, Boccia R, et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med. 2010;363:1889-1899. Bussel JB, Buchanan GR, Nugent DJ, et al. A randomized, double-blind study of romiplostim to determine its safety and efcacy in children with immune thrombocytopenia. Blood. 2011;118(1):28 36. Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag, an oral platelet growth factor, for the treatment of patients with chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007;357: 2237-47. McHutchison JG, Dusheiko G, Shiffman ML, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med. 2007;357:2227-2236. Bussel JB, Provan D, Shamsi T, et al. Eltrombopag increases platelet counts and reduces bleeding during treatment of chronic idiopathic thrombocytopenic purpura (ITP): a randomized, double blind, placebo-controlled study. Lancet. 2009;373: 641-648. Cheng G, Saleh MN, Marcher C, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a

53.

54.

55.

56.

57.

58.

6-month, randomized, phase 3 study. Lancet. 2011;377:393402. Saleh MN, Cheng G, Bussel JB, et al. EXTEND study update: safety and efcacy of eltrombopag in adults with chronic immune thrombocytopenia (ITP) from June 2006 to February 2010 [Abstract]. Blood. 2010;116:67. Bussel JB, Cheng G, Saleh MN, Mayer B, Vasey SY. Incidence of thromboembolic events across eltrombopag clinical trials in chronic immune thrombocytopenia (ITP) [Abstract]. Blood. 2010;116:70. Kuter DJ, Mufti GJ, Bain BJ, Hasserjian RP, Davis W, Rutstein M. Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim. Blood. 2009;114:3748-3756. Berchtold P, McMillan R. Therapy of chronic idiopathic thrombocytopenic purpura in adults. Blood. 1989;74:23092317. Reiner A, Gernsheimer T, Slichter SJ. Pulse cyclophosphamide therapy for refractory autoimmune thrombocytopenic purpura. Blood. 1995;85:351-358. Huhn RD, Fogarty PF, Nakamura R, et al. High-dose cyclophosphamide with autologous lymphocyte-depleted peripheral blood stem cell (PBSC) support for treatment of refractory chronic autoimmune thrombocytopenia. Blood. 2003;101:71-77.

390

American Society of Hematology